FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078452806> ?p ?o ?g. }

• W2078452806 endingPage "662" @default.
• W2078452806 startingPage "662" @default.
• W2078452806 abstract "purpose. To investigate the effect of the combined treatment of photodynamic therapy and specific VEGF165 inhibition with pegaptanib sodium (Macugen; Eyetech Pharmaceuticals, Lexington, MA) on ocular neovascularization. methods. Photodynamic therapy’s (PDT’s) effects on the integrity of pegaptanib sodium were analyzed by HPLC, a VEGF165-binding assay, and a VEGF165-induced tissue factor gene expression assay. The effects of mono- or combined treatment on vessel growth and regression were determined in a murine corneal neovascularization model. The effects of combined treatment on vessel growth were also determined in a murine choroidal neovascularization model. results. PDT did not affect the chemical composition of pegaptanib sodium nor the efficacy of pegaptanib sodium in the inhibition of VEGF165 binding to Flt-1 and VEGF165-induced gene expression. In an animal model of effects on existing ocular neovascular lesions (corneal neovascularization), PDT monotherapy yielded an initial regression of these vessels, but there followed a rapid regrowth. In contrast, pegaptanib sodium monotherapy yielded little regression but potently abrogated further vessel growth. The combination of pegaptanib sodium and PDT resulted in the regression of the neovascular lesions, as observed with PDT alone, but also prevented significant vessel regrowth, leading to a significantly greater reduction in lesion size than did each monotherapy. In addition, there was a significantly greater effect of the combination of pegaptanib sodium and PDT on lesion size in choroidal neovascularization than with each monotherapy. Pretreatment with pegaptanib sodium appeared to decrease the efficacy of PDT-induced vessel regression in corneal neovascularization, and as such the enhanced efficacy over monotherapy when the agents were delivered simultaneously was not observed. conclusions. Although the combined simultaneous treatment of ocular neovascularization with PDT and pegaptanib sodium may provide a more effective approach for the regression and overall treatment of CNV associated with AMD, the order of addition of these treatments may play a role in achieving optimal efficacy." @default.
• W2078452806 created "2016-06-24" @default.
• W2078452806 creator A5007462334 @default.
• W2078452806 creator A5009320917 @default.
• W2078452806 creator A5011752256 @default.
• W2078452806 creator A5016349256 @default.
• W2078452806 creator A5025087429 @default.
• W2078452806 creator A5032872329 @default.
• W2078452806 creator A5038506322 @default.
• W2078452806 creator A5050582691 @default.
• W2078452806 creator A5058726400 @default.
• W2078452806 creator A5080789538 @default.
• W2078452806 creator A5085600986 @default.
• W2078452806 date "2008-02-01" @default.
• W2078452806 modified "2023-09-27" @default.
• W2078452806 title "Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization" @default.
• W2078452806 cites W1485755973 @default.
• W2078452806 cites W1487528435 @default.
• W2078452806 cites W1513613431 @default.
• W2078452806 cites W1546928690 @default.
• W2078452806 cites W1601975653 @default.
• W2078452806 cites W1605245615 @default.
• W2078452806 cites W1789824814 @default.
• W2078452806 cites W1802218256 @default.
• W2078452806 cites W1967004211 @default.
• W2078452806 cites W1970142574 @default.
• W2078452806 cites W1979497736 @default.
• W2078452806 cites W1987699263 @default.
• W2078452806 cites W1997324775 @default.
• W2078452806 cites W1998424046 @default.
• W2078452806 cites W1999335460 @default.
• W2078452806 cites W2003797682 @default.
• W2078452806 cites W2004681222 @default.
• W2078452806 cites W2009828713 @default.
• W2078452806 cites W2013829983 @default.
• W2078452806 cites W2015344488 @default.
• W2078452806 cites W2016584341 @default.
• W2078452806 cites W2035353185 @default.
• W2078452806 cites W2037348124 @default.
• W2078452806 cites W2042487598 @default.
• W2078452806 cites W2045317893 @default.
• W2078452806 cites W2055635377 @default.
• W2078452806 cites W2056392188 @default.
• W2078452806 cites W2062886219 @default.
• W2078452806 cites W2071895235 @default.
• W2078452806 cites W2075634939 @default.
• W2078452806 cites W2077410508 @default.
• W2078452806 cites W2091534585 @default.
• W2078452806 cites W2091989599 @default.
• W2078452806 cites W2098582960 @default.
• W2078452806 cites W2099927130 @default.
• W2078452806 cites W2102056525 @default.
• W2078452806 cites W2127203013 @default.
• W2078452806 cites W2149201888 @default.
• W2078452806 cites W2149246673 @default.
• W2078452806 cites W2160787338 @default.
• W2078452806 cites W2983659403 @default.
• W2078452806 cites W1489281785 @default.
• W2078452806 cites W1544209267 @default.
• W2078452806 doi "https://doi.org/10.1167/iovs.07-0195" @default.
• W2078452806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18235012" @default.
• W2078452806 hasPublicationYear "2008" @default.
• W2078452806 type Work @default.
• W2078452806 sameAs 2078452806 @default.
• W2078452806 citedByCount "22" @default.
• W2078452806 countsByYear W20784528062012 @default.
• W2078452806 countsByYear W20784528062013 @default.
• W2078452806 countsByYear W20784528062014 @default.
• W2078452806 countsByYear W20784528062017 @default.
• W2078452806 countsByYear W20784528062019 @default.
• W2078452806 countsByYear W20784528062021 @default.
• W2078452806 crossrefType "journal-article" @default.
• W2078452806 hasAuthorship W2078452806A5007462334 @default.
• W2078452806 hasAuthorship W2078452806A5009320917 @default.
• W2078452806 hasAuthorship W2078452806A5011752256 @default.
• W2078452806 hasAuthorship W2078452806A5016349256 @default.
• W2078452806 hasAuthorship W2078452806A5025087429 @default.
• W2078452806 hasAuthorship W2078452806A5032872329 @default.
• W2078452806 hasAuthorship W2078452806A5038506322 @default.
• W2078452806 hasAuthorship W2078452806A5050582691 @default.
• W2078452806 hasAuthorship W2078452806A5058726400 @default.
• W2078452806 hasAuthorship W2078452806A5080789538 @default.
• W2078452806 hasAuthorship W2078452806A5085600986 @default.
• W2078452806 hasConcept C118487528 @default.
• W2078452806 hasConcept C126322002 @default.
• W2078452806 hasConcept C142724271 @default.
• W2078452806 hasConcept C178790620 @default.
• W2078452806 hasConcept C185592680 @default.
• W2078452806 hasConcept C2776694085 @default.
• W2078452806 hasConcept C2777512022 @default.
• W2078452806 hasConcept C2777802072 @default.
• W2078452806 hasConcept C2777844972 @default.
• W2078452806 hasConcept C2778271429 @default.
• W2078452806 hasConcept C2780394083 @default.
• W2078452806 hasConcept C2781100027 @default.
• W2078452806 hasConcept C2781156865 @default.
• W2078452806 hasConcept C2781323092 @default.
• W2078452806 hasConcept C502942594 @default.

• next